Successful treatment of acute promyelocytic leukemia in pregnancy with all-trans retinoic acid
TO THE EDITOR Management of APL during pregnancy represents a significant problem because it is usually associated with coagulopathy and the potential teratogenic effect of most chemotherapeutic agents. There have been fewer than 20 reported cases of acute promyelocytic leukemia (APL) in pregnancy treated with all-trans retinoic acid (ATRA) alone or in combination with cytotoxic chemotherapy. Even though ATRA has been shown to induce complete remission in most cases of newly diagnosed APL with rapid resolution of disseminated intravascular coagulation, its effectiveness and safety in pregnancy has not been confirmed due to limited clinical experience. We herein report a patient diagnosed as APL at the 25th week of gestation who was successfully treated with ATRA. Treatment with ATRA alone resulted in hematological remission on day 25 of therapy with no significant adverse effect. A healthy infant was delivered by Caesarean section at the 34th week of gestation. To date, the patient is still in complete remission and the growth and development of her 9-month-old infant has been without any complication.
A 41-year-old woman, gravida 7, para 3 + 3, presented at the 25th week of gestation with fatigue and fever for 2 weeks. The maternal hemoglobin level was 4.0 g/dl, platelet count 12 × 10 9 /l and leukocyte count 0.7 × 10 9 /l with a differential of 40% promyelocytes, 20% segmented neutrophils, and 40% lymphocytes. Morphological, immunophenotyping and cytogenetic studies of the bone marrow samples were consistent with the diagnosis of APL. The INR, partial thromboplastin time, and serum fibrinogen were within normal limits. The patient received broad-spectrum antibiotics resulting in resolution of the fever. ATRA was initiated at a dose of 45 mg/m 2 /day orally. Her blood counts gradually improved and she did not require further transfusion support after 19 days of ATRA therapy. Eleven units of irradiated packed red cells and 13 units of platelets were used. Ultrasound examination at the 32nd week of gestation revealed a normalappearing fetus, and a low-lying placenta. Dexamethasone 12 mg twice a week was administered for fetal pulmonary maturity. The hemoglobin was 10.2 g/dl, platelet 198 × 10 9 /l and leukocyte 3.8 × 10 9 /l with normal differential count by day 25 of ATRA therapy. No complication associated with ATRA was observed. Treatment with ATRA was continued for 56 days until a live baby girl was delivered by Caesarean section at the 34th week of gestation. The birth weight was 2610 g and there were no physical abnormalities detected. Blood tests including blood count and cholesterol levels were normal. The maternal postpartum course was uneventful and she was discharged home on postpartum day 5 on ATRA therapy. Two weeks after delivery, a repeat bone marrow confirmed complete hematological and cytogenetic remission. The patient has since received two courses of standard consolidation and maintenance chemotherapy. At the time of writing, the patient and her 9-month-old child are presently well.
APL in pregnancy is a rare event, with fewer than 60 cases reported in the literature. Most early deaths during remission induction therapy have been caused by sudden intracranial or pulmonary hemorrhage in association with DIC. Elevated circulating levels of clotting factors contribute to the hypercoagulable state of pregnancy and may increase the likelihood of developing DIC. While conventional cytotoxic chemotherapy has been shown to exacerbate DIC, ATRA has been demonstrated to improve DIC. 1 Furthermore, it does not induce bone marrow hypoplasia with its consequent pancytopenia and increased risk for infection. There is no cytotoxic damage to the Leukemia tissues. The most serious maternal adverse effect of ATRA is the potentially lethal retinoic acid syndrome (RAS) characterized by fever, dyspnea, pulmonary infiltrates, pleural or pericardial effusion and episodic hypotension which may be reversed with early administration of corticosteroids. 1 The high frequency of hyperleukocytosis and RAS following the use of ATRA has been clearly demonstrated from previous reports (nine of 16 cases), however the explanation for this phenomenon is still lacking. Malformations involving craniofacial, cardiac, thymic and central nervous system have been observed following the use of 13-cis-retinoic acid in early pregnancy. In contrast, specific malformation associated with the use of ATRA has not been described. However, its use in the third trimester has been reported to cause fetal arrthythmia, 2 fetal growth retardation 2 and premature delivery. 3 The successful use of ATRA for the treatment of APL in pregnancy was first described in 1994. 4 Prior to ATRA, only eight of 12 pregnancies with APL treated with standard chemotherapy resulted in live birth. 5 In contrast, all the 16 cases of APL in pregnancy treated with ATRA alone or in combination with chemotherapy resulted in a favorable outcome. Table 1 summarizes 16 cases (including the present case) of APL in pregnancy treated with ATRA. In all but two cases, 5, 6 chemotherapy was not used in conjunction with ATRA therapy. Complete remission was obtained in all patients with no serious adverse effect. The products of all the pregnancies, although premature, survived and developed normally during a relatively brief observational period except for two children who were observed up to 2-4 years of age. Two babies had cardiac symptoms at birth: one had atrial arrhythmia which resolved spontaneously, 2 while the other child sustained cardiac arrest immediately following birth, 7 which was successfully resuscitated. No teratogenic effect was observed. This case, together with the cases described above demonstrated that pregnancy might proceed normally during treatment with ATRA. This drug is safe and well tolerated, if the retinoic acid syndrome can be prevented or managed, as compared with standard chemotherapeutic agents.
In the present case, the reasons for early delivery at 34 weeks (total of 8 weeks of ATRA) included: first, to minimize the complications associated with prematurity; second, to avoid life-threatening hemorrhage from the low lying placenta; and third, to prevent the development of resistance to ATRA, as there were reports in the literature that more than 90% of patients achieving complete remission eventually develop resistance to ATRA and relapse within a few months. 8 In conclusion, as suggested from the present and previous reports, ATRA alone, followed by consolidation chemotherapy after delivery, could constitute an alternative strategy for the treatment of APL diagnosed beyond the first trimester of pregnancy. While the safety of ATRA therapy in the first trimester of pregnancy has not been confirmed, it seems to be reasonably safe during the second and third trimesters. ATRA at a dose of 45 mg/m 2 /day can be given in the second or third trimester of pregnancy with reasonable safety to the mother and the fetus. However, close monitoring for fetal cardiac complications is mandatory throughout the pregnancy and long-term follow-up of children born to mothers who underwent ATRA treatment is warranted to assess clearly the long-term sequelae of ATRA therapy to these children. 
